Recruiting PHASE1/PHASE2 INTERVENTIONAL 2-arm NCT06985355

A Study of MHB046C Injection in Patients With Advanced Solid Tumors

A Phase I/II Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of MHB046C Injection in Patients With Advanced Solid Tumors

Sponsor: Minghui Pharmaceutical (Hangzhou) Ltd

Conditions Advanced Solid Cancer

Interventions MHB046C

Updated 2 times since 2025 Last updated: Sep 16, 2025 Started: Jul 17, 2025 Primary completion: May 31, 2029 Completion: May 31, 2031

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT06985355, this PHASE1/PHASE2 trial focuses on Advanced Solid Cancer and remains actively recruiting participants. Sponsored by Minghui Pharmaceutical (Hangzhou) Ltd, it has been updated 2 times since 2025, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Status Flow

Change History

2 versions recorded

Oct 2025 — Present [monthly]

Recruiting PHASE1/PHASE2

Status: Not Yet Recruiting → Recruiting
Jun 2025 — Oct 2025 [monthly]

Not Yet Recruiting PHASE1/PHASE2

First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Minghui Pharmaceutical (Hangzhou) Ltd

Data source: Minghui Pharmaceutical (Hangzhou) Ltd

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Guangzhou, China